This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Biotinylated Human ACE2 / ACEH Protein, His,Avitag™ (MALS verified)
catalog :
AC2-H82E6
quantity :
200 ug, 25 ug
price :
1570 USD, 380 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
AC2-H82E6
product name :
Biotinylated Human ACE2 / ACEH Protein, His,Avitag™ (MALS verified)
quantity :
200 ug, 25 ug
price :
1570 USD, 380 USD
quantity & price :
$380/25ug,$1570/200ug
target :
ACE2
host species :
Human
By Tag :
His Tag & Avi Tag
Research :
For Research Use Only
Source :
Biotinylated Human ACE2, His,Avitag (AC2-H82E6) is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Ser 740 (Accession # Q9BYF1-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Biotinylated Human ACE2, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with glycerol as protectant. Contact us for customized product form or formulation.
Storage :
Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● The product MUST be stored at -70°C or lower upon receipt;
● -70℃ for 24 months under sterile conditions.
Background :
Angiotensin-converting enzyme 2 (ACE2) is also known as ACEH (ACE homolog), is an integral membrane protein with considerable homologous to ACE, which belongs to the peptidase M2 family. ACE2 is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin, or the conversion of angiotensin II to angiotensin 1-7. ACE2 may be an important regulator of heart function. In case of human coronaviruses SARS and HCoV-NL63 infections, ACE-2 serve as functional receptor for the spike glycoprotein of both coronaviruses. ACE2 is activated by chloride and fluoride, but not bromide and Inhibited by MLN-4760, cFP_Leu, and EDTA, but not by the ACE inhibitors linosipril, captopril and enalaprilat. ACE2 is active from pH 6 to 9, and the optimum pH is 6.5 in the presence of 1 M NaCl.
References :
(1) Turner AJ., et al., 2002, Can. J. Physiol. Pharmacol. 80 (4): 346–53.
(2) Katovich MJ., et al., 2005, Exp. Physiol. 90 (3): 299–305.
(3) Donoghue M., et al., 2000, Circ. Res. 87:E1-E9.
(4) Tipnis S.R., et al., 2000, J. Biol. Chem. 275:33238-33243.
(5) Vickers C., et al., 2002, J. Biol. Chem. 277:14838-14843.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments